XLife fund

Xlife Sciences AG operates as a Swiss accelerator dedicated to fostering the development and commercialization of nascent research projects within the expansive life sciences domain. The firm specializes in advancing promising innovations from universities and research institutions across technology platforms, biotechnologies, medical technology, and artificial intelligence in digital health, aiming to bridge the gap between scientific discovery and practical healthcare applications.

Established in Zurich, Switzerland, Xlife Sciences AG commenced its focused operations around 2019, with Oliver R. Baumann assuming the role of CEO. His leadership is central to the company’s strategic direction, driven by an entrepreneurial vision to transform the healthcare landscape by systematically identifying and nurturing groundbreaking scientific endeavors with high potential.

The ultimate beneficiaries of Xlife Sciences AG’s work are patients, as the company strives to deliver tangible solutions for significant unmet medical needs and enhance overall quality of life. The company’s long-term vision is to serve as a pivotal conduit, meticulously guiding pioneering scientific research through the complex stages of development into impactful healthcare solutions.